Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.

News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
-is-malignancy-of-the-esophagus-cancer-of-the-esophagus-ct-with-contrast.jpg?sfvrsn=70ef5f67_1)
New study reveals how oesophageal cancer adapts to treatment
Researchers have tracked how the most common form of oesophageal cancer and its immune environment change during a standard form of treatment – offering vital clues that could shape future therapies, so they work for longer.

Newly discovered role of enzyme could explain link between diabetes and cancer
Cell biologists have made a significant advance, uncovering the key role of an enzyme in determining the physical structure and behaviour of cancer cells, including how they spread.

ICR researcher awarded prestigious lectureship for practice-changing breast cancer research
Dr Maggie Cheang, a breast cancer researcher at The Institute of Cancer Research, London, has been awarded the prestigious CL Oakley lectureship.

Scientists find new way to predict how bowel cancer drugs will stop working
Scientists from The Institute of Cancer Research, London, have developed a tool that can predict how bowel cancer adapts to treatment – helping researchers to design new personalised drugs that will keep patients living well for longer.